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Abstract
Khush Singh Aujla: Angiotensin II as a Potential Regulator of Inflammatory Cytokine
Induced Hypertension in Systemic Lupus Erythematosus.
(Under the direction of Dr. Mika Jekabsons)
The disease Systemic Lupus Erythematosus is a chronic inflammatory,
autoimmune disorder that primarily affects women during their reproductive years.
Women with SLE are at a greater risk of developing hypertension, which increases their
risk of mortality from a cardiac related event. A proposed mechanism for SLE
hypertension suggests that inflammation in the kidneys causes renal dysfunction,
presumably resulting in less water excretion, increased plasma volume, and thus high
blood pressure. This experiment tests the hypothesis that the T-cells from a mouse model
of SLE hyper secrete the inflammatory cytokines IL-17, IL-10, and DFN- y, and are more
sensitive to the cytokine-stimulating hormone angiotensin II(ANG II). To test this
hypothesis, T lymphoc}^es were isolated from control and SLE mice, and cj^okine
secretion into the culture media was determined in the presence or absence of ANG II.
Thymocytes from SLE mice secreted greater levels of all three inflammatory cytokines,
although excess IL-17 secretion occurred only after the onset of renal damage.
Angiotensin II increased production of IFN- y, but there was no major difference between
the SLE and Control groups. These results indicate that hyper secretion of IL-17, IL-10,
and IFN- y by SLE T-cells may be contributing to renal inflammation, kidney damage,
and therefore SLE hypertension. T-cell hypersensitivity to ANG II could not account for
the hypertension, suggesting that these cells are excessively sensitive to another factor
(that is present in the culture media) or have an innately higher secretion rate.
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Introduction

Systemic Lupus Erythematous(SLE)is a chronic inflammatory, autoimmune
disorder. In this disease immune cells mistakenly identify their own host tissue as foreign
threats, and cause excessive inflammation. Prolonged inflammation leads to swelling and
continued recruitment of immune cells, which degrade the body’s cells and tissues (1). A
positive diagnosis for SLE is confirmed if at least four of the criteria listed by the
American College of Rheumatology are met(Table 1). The symptom most often
exhibited by SLE patients is a malar rash, which creates a butterfly pattern across the
cheeks and nose (1). This distinct feature is also similar to a wolfs facial design, giving
the disease its trademark name. Lupus.

SLE is a complex disease that can potentially affect any organ system during a
flare, or a period of elevated disease activity. Alternatively, in some patients it can be
effectively managed such that long periods of remission are possible (2). SLE is a gender
specific disorder, with females about nine times more likely to develop the disease.
Furthermore, the disease is most commonly active during women’s reproductive years.
The pathogenesis of SLE remains unclear, but it is likely that several genetic,
environmental, and hormonal factors may be involved (3). Current treatments for SLE
target decreasing the frequency offlares, and reducing their inflammatory effects once
they occur (2).

For many patients’ advances in general medical care has improved the short-term
prognosis for SLE. Yet there is still no cure for this disease, and the chronic inflammation
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Criterion

Description

Malar rash

"Butterfly" shaped rash across the cheeks

Discoid rash

Skin rash in the shape of a coin or an oval

Photosensitivity

Skin rash caused by a reaction to sunlight

Oral ulcers

Oral or nasopharyngeal ulcers

Nonerosive arthritis

Tenderness, swelling, or effusion of peripheral
joints

Pleurltis, pericarditis

Inflammation or effusion of the covering protecting
the heart and lungs

Renal disorder

Proteinuria, cellular casts

Neurological disorder

Seizures, psychosis

Hematologic disorder

Hemolytic anemia or leukopenia

Immunologic disorder

Anti-DNA, antl-Sm, or antl-phosholipid antibodies

Positive antinuclear antibody

Anti-nuclear antibodies

Table 1: Diagnostic Criteria for SLE. List of common criteria used in diagnosing Systemic
Lupus Erythematosus, based on recommendations from the American College of Rheumatology.
A positive diagnosis of lupus is commonly confirmed if four of the listed criteria are present.
Most patients initially present with the malar rash on the face, or the discoid rash throughout the
skin. The most prominent sign of SLE is the presence of autoimmune antibodies in the blood; the
immunologic disorder is seen in almost all SLE patients. If untreated the disease can lead to
inflammation in several different areas (brain, kidney,joints...etc) and cause severe complications
(psychosis, nephritis, arthritis, etc...) in those areas.(Smith)
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can degrade tissue structure throughout the body, resulting in loss of organ function (2).
Trager and Ward found that the probability of survival for SLE is 95% at 5 years, but
78% after 20 years (4). The primary cause of mortality after the first five years is
cardiovascular disease, with dysfunctions found in the heart and/or blood vessels.
Women between 15 and 44 years of age with SLE are at a 50% greater risk of dying from
a cardiac related mortality than their age-matched healthy counterparts (5). One of the
major risk factors for a cardiac event is hypertension, a medical condition characterized
by chronically high blood pressure clinically diagnosed as systolic/diastolic pressures
greater than 140/90 mmHg. Elevated blood pressure causes the heart to work harder as a
greater force is required to pump blood against the higher pressure. The greater workload
increases the risk of heart failure. Additionally, high arterial pressure increases the risk of
stroke stemming from rupture of an artery (6). Studies have shown that women with SLE
have a much greater chance of developing hypertension than women without SLE (7).
Despite a stark contrast, little is known about the mechanisms behind the high prevalence
of hypertension in SLE patients.

The kidneys play an important role in the long-term regulation of blood pressure
by regulating plasma volume. Therefore, it is important to consider their function during
any condition that leads to hypertension. Through a controlled balance of excretion and
absorption, the kidneys regulate blood fluid volume, electrolyte levels, osmolarity, and
acidity. Each kidney appears as a bean-like structure, and is connected to the bladder by
the ureter. The renal circulation receives a fifth of cardiac output through the renal artery
(8). Within the kidney are functional units known as nephrons. Blood enters the nephrons
by the afferent arterioles, and is partially filtered into nephron tubules by the glomerular
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capillaries, while the unfiltered blood exits through the efferent arterioles. The renal
vascular resistance(RVR)to blood flow in the afferent arteriole controls the blood flow
into the glomerular capillaries. The nephron tubules into which the filtered blood enters,
consist of the following segments in the order the filtrate circulates through them: the
Bowman’s capsule, the proximal tubule, the loop of Henle, the distal tubule, and the
collecting duct (Figure 1). The filtrate is formed when bulk flow moves fluid out of the
plasma along with small electrolytes and waste. Plasma proteins like albumin and red
blood cells are too large to pass through the Bowman’s capsule, and their presence in the
urine usually indicates kidney dysfunction (9). The glomerular filtration rate(GFR)is a
key measure of kidney function, and is determined by analyzing the amount of plasma
filtered per minute. RVR partly determines GFR by affecting glomerular capillary
pressure, a major force driving filtration. The balance of filtered water in the nephron that
is excreted or reabsorbed in to the plasma ultimately determines blood volume and thus
blood pressure (8).

Since the kidneys are the long-term regulators of blood pressure, hypertension is
accompanied by a change in renal hemodynamics. One of the main symptoms of SLE is
lupus nephritis, in which the immune system attacks the kidney tissue. The condition is
categorized in six morphological classes depending on severity, and it is estimated that as
high as 50% of patients with SLE can develop some form of lupus nephritis (10). As
immune cells attack the kidney, one consequence can be destruction of glomerular
capillaries and Bowman’s capsules, which will effectively decrease kidney GFR if a
critical number are lost. Hence less water will be filtered for excretion, potentially
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Figure 1: Diagram of the Nephron. Blood arrives at the glomerulus for filtration through the
afferent arteriole. About 25% of the plasma passes through the filtration barrier to become the
glomerular filtrate in Bowman’s capsule. Blood cells, most of the proteins, and about 75% of the
fluid leave the glomerulus via the efferent arteriole. Filtration and reabsorption of different
molecules occurs throughout the convoluted tubules. The remaining waste is gathered in the
collecting duct and is sent to the ureter (illustration reproduced from reference 8). During SLE
inflammation’ T-cells are seen surrounding the glomerulus, afferent arterioles, and convoluted
tubules.
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causing increased plasma volume, and thus increased blood pressure (Figure 2). Nakano
et al showed that reduction in GFR correlated with the severity of lupus nephritis (11).
Since this condition affects blood pressure, it is easy to assume that SLE hypertension is
only dependent on nephritis. However, not all patients with SLE develop nephritis, but
can still be at risk of developing hypertension. It has been shown that hypertension
correlated strongly with SLE patients that had dysfunctions in their renal hemodynamics,
but did not have lupus nephritis (12). This suggests that there are additional physiological
mechanisms contributing to hypertension in SLE, which change renal hemodynamics in
another way then nephritis. Yet, previous research has demonstrated that this change is
occurring through a reduction in GFR and RBF(11).

The underlying cell and molecular mechanism responsible for the renal
dysfunction in patients with SLE hypertension remains unclear. Given the autoimmune
nature of this disease, it is has been hypothesized that the immune system plays a role
(13). Several experiments have shown a potential role for the immune system in models
of hypertension. It has been shown that inflammation may be a major contributing factor
to the development of Angiotensin II(ANG II) model of hypertension as well as kidney
damage in rats. Carretero et al showed that by knocking out a gene for the CCR2
chemokine receptor, which is important in the recruitment of macrophage cells to the
kidneys, ANG II infused hypertension and kidney damage were attenuated (14).
Experiments have shown that immunosuppressant agents such as mycophenolate mofetil
(MMF)are able to suppress many of the symptoms of hypertension in rat models (15).
Mattson et al showed that MMF reduced levels of T lymphoc)^es (T-cells) as well as B
lymphocytes (B-cells) infiltrating the kidney, and also significantly decreased the blood
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SLE

O
Autoimmune Cells

O
Autoimmune Response to Renal Tissue

O
Renal Inflammation

O
Loss of Functioning Nephron Units

O
Decreased Glomerular Filtration
Rate/Increased Water Retention

Lupus Nephritis Induced Hypertension

Figure 2: Mechanism for lupus nephritis induced hypertension. SLE patients have
autoimmune cells, or cells that are more prone to have an inflammatory response to host tissue.
The immune cells create antibodies that target renal tissue, which leads to inflammation in the
kidneys. The inflammation can damage several parts of a nephron, including the Bowman’s
capsule and glomerular capillaries. The degradation of the nephron will lead to a decrease in
in
glomerular filtration rate, and therefore more water retention by the kidneys. The increase
plasma volume will raise blood pressure above 140/90 mmHg systolic over diastolic, and
therefore induce hypertension.
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pressure in comparison to rats treated with vehicle. The immune suppression was also
shown to attenuate kidney damage,indicated by decreased urine albumin levels as well as
less glomerular damage (16). T-cells are suspected to play an important role in
connecting inflammation and hypertension. Experiments on the Dahl salt sensitive rat
model of hypertension showed that T-cells played an active role in the progression of
hypertension as well as kidney damage. In this model, increased renal infiltration of Tcells correlated with increased blood pressure, increased albumin in the urine, and
resulted in renal glomerular and tubular damage (17). Since autoimmune responses are
the basis of inflammation in SLE,immunosuppression to attenuate the inflammation is
likely to reduce the degree of hypertension. However, suppressing inflammation once it
has started still leaves the patient susceptible to damage. Instead it is potentially more
beneficial to target the mechanism that triggers inflammation in SLE.

Immune cells are initially activated by antigens, and secrete several different
cytokines into the circulation to recruit more cells thus producing inflammation.
Cytokines are cell-to-cell paracrine factors that work by binding to specific cell surface
receptors, and altering the cell’s function. This can include changing the expression of a
gene by affecting transcriptional factors, or causing the production or suppression of
other cytokines. The effects on the cell vary according to cell type and by individual
cytokines, but all cytokines fall into distinct family classifications (18). It has been shown
that several inflammatory cytokines are increased in the tissues and plasma of patients
with SLE,suggesting that they may play a role in SLE hypertension (13). In this respect,
three cytokines of interest are interleukin 17(IL-17), interleukin 10(IL-10), and
interferon gamma(BFN- y). IL-17 is known to be a pro-inflammatory cytokine that
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stimulates certain immune cells to produce other cytokines, and is linked to several
autoimmune diseases (19). Experiments have shown that IL-17 is increased in the plasma
of SLE patients. This has lead to the hypothesis that IL-17 plays an important role in the
pathogenesis of SLE (20). The cytokine IL-10 is actually considered an anti
inflammatory cytokine because it down regulates the activity of T-helper cells. However
IL-10 activates B-cells to produce antibodies, which in an autoimmune disease, become
auto antibodies that mistake host tissue as threats. This in turn causes a greater
inflammatory response than the original anti-inflammatory benefits of IL-10(21). It has
been shown that the plasma level of this cytokine by T-cells is increased in patients with
SLE, and the plasma levels have positively correlated with the severity of the SLE (22).
The pro-inflammatory cytokine EFN- y stimulates other immune cells during
inflammation, and experiments have shown an increase in the cytokine levels in certain
blood cells from patients with SLE (23). New approaches for SLE treatment include
therapies where IFN- y related genes are suppressed (24).

There are at least two possible mechanisms that can account for the increased
plasma levels of these cytokines. First, a greater number of immune cells may be present,
so that the collective rate of cytokine secretion into the plasma is greater. Second, the
existing population of immune cells may be hyperactive, and thus secreting more
cytokines per cell. My hypothesis is that the later explanation is true, although these
hypotheses may not be mutually exclusive. This surplus of cytokines may recruit
additional immune cells into the kidneys that increase renal inflammation, which impairs
the renal regulation of blood pressure, and ultimately leads to hypertension. The goal of
this study was to determine the mechanisms responsible for this overproduction.
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The hormone ANG II may be a potential cause for the increase in inflammatory
cytokines in SLE hypertension. ANG-II is a part of the renin angiotensin system, and is a
major regulator of blood pressure. The molecule works by indirectly increasing the
reabsorption of Na^ by the distal tubule as well as the collecting duct, which leads to
water reabsorption through osmosis. It can also reduce GFR and the plasma flow through
the kidneys by causing arteriole vasoconstriction. ANG-II binds to specific receptors on
cell surfaces, which are common dmg targets to lower blood pressure (8). Chronic
infusion of ANG-II has been shown to induce hypertension in mice. Furthermore,
experiments have supported the idea that ANG-II at least partially promotes hypertension
by affecting T-cells (25). One experiment showed that mice, which were genetically
engineered to lack T and B-cells, did not become hypertensive under chronic ANG-II
infusion. Yet, when only the T-cells were administered back into the knockout mice, and
ANG-II was chronically infused, the hypertension returned.(26). It is thought that by
activating the T-cells, ANG-II is inducing the production of inflammatory cytokines. It
has been shown that ANG-II increases the production of pro-inflammatory c}^okines
when inducing hypertension (27). Similarly, the blocking of the ANG-II receptor has
been shown to have anti-inflammatory effects by decreasing the production of the proinflammatory cytokine IFN- y (28).

In this study, an additional hypothesis to be tested is that the hormone ANG-II
increases the production of the inflammatory cytokine IFN- y by T-cells. There is no
conclusive evidence that ANG-II levels are elevated in patients with SLE. Yet ANG-II is
seen to both correlate with the production of certain inflammatory cytokines by T-cells,
and with the presence of hypertension. Since SLE is an inflammatory disorder with an
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increased risk of hypertension, my last hypothesis is that ANG-II will increase the
production of inflammatory cytokines to a greater extent in SLE T-cells. A proposed
model for the role of T-cells, ANG II, and inflammatory cytokines in the development of
SLE hypertension is outlined in Figure 3.
I

I;

!

I
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SLE

O
Irregular T-cells

O
T-cells Activation
●Stimulated by ANGII

Inflammatory Cytokines (IL-10, IL-17, DFN-y)

O
Recruitment of Immune Cells

O
Renal Vascular/Glomerular Inflammation

O
Increased Renal Vascular Resistance/Decreased
Renal Blood Flow

O
Decreased Glomerular Filtration Rate/Increased
Water Retention

O
SLE Hypertension

Figure 3: Proposed Mechanism for SLE Hypertension. SLE patients have irregular T-cells, or
cells that are more prone to produce an inflammatory response. A possible tngger tor oi-activation in the kidneys is ANG II. The T-cell activation may lead to an increase in the
production of inflammatory cytokines, which recruit other immune cells to the kidneys through
circulation. This leads to inflammation in the renal vasculature, which elevates RVR, and
therefore a decrease in renal blood flow. Without adequate blood flow to the glomerulus, the GFR
a nse
decreases, and thus the kidneys excrete less water. The increased plasma volume results in
in resting blood pressure above 140/90 mmHg systolic over diastolic. If the elevated blood
pressure becomes chronic, hypertension develops.
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Specific Aims

This Study tests the hypothesis that T-cells from a mouse model of SLE secrete
more of the inflammatory cytokines BL-17, D-10, and IFN- y than T-cells from non-SLE
control mice, and that ANG-II increases the production of IFN- y to a greater extent in
SLE then Control T-cells. The specific aims were to:

(i)

Isolate T-cells from control and SLE mice.

(ii)

Determine the baseline secretion of IL-17, IL-10, and IFN- y in a defined cell
culture medium.

(iii)

(iv)

Determine the sensitivity of T-cells’ IFN- y secretion to ANG-II.

Compare EFN- y secretion changes in the presence of ANG-II between SLE and
Control T-cells.
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Materials and Methods

Animals

Dr. Michael Ryan (Department of Physiology, University of Mississippi Medical
Center) provided female strains of mice for the experiment. The offspring of a cross
between the New Zealand Black crossed and the New Zealand White(NZBWFl)mice al
spontaneously developed SLE, the origin of which is unknown. NZBWFl mice exhibit
several characteristics similar to human SLE, most importantly their development of
hypertension (Figure 4). The NZW (Control mouse) model was used to represent healthy
conditions. This model is a common parental control for the NZBWFl model, and does
not display characteristics of human SLE. Both strains had their urine albumin levels
measured regularly as an index of renal function, with trace levels meaning the lowest
detection limit and 2000 mg/L the highest. After thirty-six weeks’ the NZBWFl mice
began to develop hypertension, with blood pressure elevating close to 140/90 mmHg
systolic over diastolic, at which point both groups were sacrificed.

Mouse spleenocyte (spleen immune cells) isolation.

(All buffers and solutions used to isolate the Spleenocytes were from the Mouse
Spleen T-cell Isolation Kit by Life Technologies.) Each mouse was prepared for
dissection, and cleaned with 70% ethanol. The abdominal cavity was cut open, and the
spleen was removed and placed in a cell strainer. The spleen was then mashed through
the strainer into a petri dish, and the remaining cells in the strainer were rinsed out with 5
ml of RPMI (cell culture) buffer. The cell suspension was transferred into a 15 mL
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Figure 4: Mean Arterial Pressure for Control and SLE Mice. The data in this figure is taken
from reference number 13, and represent published data from Dr. Michael Ryan (University of
Mississippi, Department of Physiology). Comparing the mean arterial pressure(MAP)in mmHg
between female NZBWFl and NZW mice. On average the SLE mice had significantly higher
blood pressure (140 mmHg)then the control mice (115 mmHg).
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conical tube, and centrifuged at 1600 revolutions per minute(rpm)for 9 minutes. The cell
pellet of spleen cells was suspended in 1 ml of an ACK buffer, to lyse all the red blood
cells in the pellet. Afterwards another 9 ml of RPMI buffer was added, and the mixture
was centrifuged. The supernatant was discarded to remove all dead cells. The remaining
pellet consisted only of viable spleenocytes, and was resuspended in 3 ml of RPMI
buffer. The sample was run through a cell counter to determine the amount of cells that
had been isolated.

Dynabeads Mouse CD4+ T-cell Isolation.

(All buffers and solutions used to isolate the T-cells from spleenocytes were from
the Dynabeads Mouse CD4+ T-cell Isolation Kit by Invitrogen.) Dynabeads are protein
A-coated microscopic beads that bind to mouse antibodies T-cell specific CD4-I- plasma
membrane receptors. After the spleenocytes were counted, they were washed again and
then resuspended at one million cells in 500ul of isolation buffer and 25ul flowcomp
mouse CD4 antibody. The mixture was stirred and incubated at 2 °C for ten minutes.
Afterwards 2ml of isolation buffer were added to wash the cells, followed by
centrifugation, and removal of the supernatant. The cell pellet was resuspended in 1 ml of
isolation buffer, and transferred to a 1.5 ml eppendorf tube. Protein A Dynabeads, 75 pL
were washed and then transferred to the cell suspension. After fifteen minutes of
incubation, the tube was placed on a magnet. The Dynabeads with the CD4-H T cells
attached were retained in the tube by the magnet, while the remaining supernatant
containing other splenocytes was discarded. The Dynabeads were then washed twice in
isolation buffer. Next the Dynabeads were resuspended in 1 ml of flowcomp release
buffer, which caused the cells to detach from the antibodies. The cells were then remixed

16

and replaced on the magnet. This time the cells remained in the supernatant and only the
Dynabeads with the attached antibodies adhered to the tube by the magnet. The
supernatant containing the cells was removed and placed in a 15 ml tube. Next 2 ml of
isolation buffer was added and the suspension centrifuged. The supernatant was discarded
and the remaining pellet was resuspended in 2 ml of RPMI buffer. The remaining
solution contained only CD4+ T-cells. A sample of the solution was run through a cell
counter to determine the number of CD4+ T-cells that had been isolated.

CD4-\- T-cell activation and culturing.

To activate the T-cells to produce inflammatory cytokines, they had to be
stimulated. Each cell culture was prepared by mixing 1 million T-cells with a cell culture
media, consisting of 10% fetal bovine serum in RPMI buffer supplemented with 10 pM
IL-2 to stimulate T-cell cytokine production. To determine the amount of media to use
per sample, calculations were based on the population of T-cells isolated (calculations A).
The combined T-cells media was then plated into each well of a 8 well chamber. To
stimulate mitosis, 25pL of CD3/CD28 Dynabeads were added to each well of cell culture.
The cells in the culture were allowed to attach to the bottom surface, over 48 hours in 5%
CO2, 37°C incubator. After incubations, the cells had proliferated to greater quantities,
and released a mixture of inflammatory cytokines into the media (figure 5).

Measurement ofinflammatory cytokine production.

After incubation different assays were run on the culture media to measure
cytokine levels. IL-17 and IL-10 were measured using Mouse IL-17 and IL-10
immunoassays from Quantikine. The assays were prepared in a 96 well plate, and all
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reagents were included in the assay kit. To each well 50jnL of either a standard sample, a
control, or an unknown sample was added with 50jiL of assay diluent. The wells were
incubated for 2 hours, washed, and then lOOpL of conjugate was added to each well.
After another wash, lOOpL of substrate solution was added to each well, and incubated
for 30 minutes. The substrate solution caused the samples to change color based on the
amount of the cytokine they contained. Adding a stop solution stopped the reaction, and
then the 96 well plate was read in a spectrophotometer at 570 nm.

The IFN- Y was measured using an ElISPOT assay. The assay was run in a 96
well Millipore plate, and all reagents used were included in the assay kit. First the plate
was coated with lOOmJL of coating antibodies at 15mg/ml, and incubated overnight. Next
a lOOpL of the standards, controls, and T-cell media samples were added to each well,
and incubated for 40 hours. After incubation the wells were washed six times in distilled
water. A lOOpL of 1 mg/ml diluted IFN- y was added to each well, and incubated for an
hour. A 1 OOpL of blocking buffer was added to each well, and incubated until dark spots
appeared on the plate bottoms. The plate was then washed in distilled water, and the spots
were counted using an automated machine. Due to time and resource constraints only the
IFN- y protocol was repeated in the presence of ANG-II. Half of the cell plates from both
the SLE and control group received 10 uM of ANG-II(calculations B). An IFN- y
ELISPOT assay was repeated to measure the effects of ANG-II. All figures were
calculated using Microsoft Excel.
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Calculations

A.

T cells and culture media

●

Count isolated T cells (cells/ml)

●

Plate each well (5 wells per sample) with 1 million T-cells in a total volume of
1.5 ml

((# Isolated T-cells)/(le^6 cells)) = ((1.5 ml)/(X))

X = volume of cells per well

(1.5 ml)-(volume of cells per well)=(volume of media per well)

((Volume of cells per well)/(1.5 ml))=((volume of media per well)/(X))
X

total volume of culture media needed.

Example:

X = 230 ul(volume of cells per well)

6.5e6 cells / le6 cells = 1.5 ml/X

1.5 ml - 230 ul = 1, 270 ul (media per well)

230 ul / 1,500 ul= 1,270 ul/X

●

X = 8, 282 ul (media total)

Combine total volume of media needed directly to the volume of T cells

Plate each well with 1.5 ml of the combined T cells and media
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B.

Angiotensin II (Molecular Weight = 1046.18 g/mol)

●

Add 10.4 mg of ANG II into 10 ml of distilled water for a stock solution
(concentration = lOmM). Dilute the stock solution, take 1 ml and add to 9 ml of
distilled water for a work solution (concentration = ImM).

Add 20ul of work solution into half of the wells (final concentration added =10 uM)
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Results
IL-IO secretion is greaterfrom SLE then Control T-cells.
Figure 5 illustrates the difference in IL-10 secretion by SLE and Control T-cells
stimulated by IL-2 and Dynabeads. The two SLE mice had severe albumin (2000)levels,
while the two control mice had minor (trace). Analysis of the IL-10 immunoassay
showed that IL-10 secretion for SLE T-cells was almost four times that of Control Tcells, 243 pg/ml to 65 pg/ml. This suggests that SLE T-cells are producing IL-10 at a
greater rate then healthy T-cells in the presence of IL-2 and Dynabeads.

IL-17 secretion is similar between Control and SLE T-cells with low albumin, but higher
in SLE T-cells with high albumin.

An immunoassay for IL-17 originally showed minor differences between the
Control and SLE group, but there was a major difference between the two T-cell
preparations from the SLE mice. One mouse had similar IL-17 levels to control, while the
other had double the concentration production. When checking previous notes it was
apparent that the SLE mouse with higher EL-17 levels was the mouse with very high
levels of albumin in the urine. The urine of the mice had been checked daily, and albumin
levels were indicated on a rudimentary scale that measured from trace (none) to 2000
(severe). Figure 6 illustrates that greater level of albumin in the urine correlated with
greater IL-17 production. The Control mice had no measurable Albumin, while one SLE
mouse had an albumin level of 100(minor). The two groups had approximately the same
levels of IL-17 production by their T-cells, 13.4 pg/ml to 13.7 pg/ml. As for the mouse
with severe albumin in the urine, it’s IL-17 production of 27.3 pg/ml was double that of
the Control group and the other SLE mouse. This suggested that SLE T-cells do not
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Figure 5: IL-10 Secretion by T-Cells. Media collected from T-cell cultures of Control and SLE
mice. T-cell cultures were incubated with CD3/CD28 Dynabeads and EL-2 to stimulate baseline
rate of IL-10 secretion, and assayed for IL-10 levels 48 hours after plating one million cells. Tcells collected from SLE mice secreted approximately 243 pg/ml of IL-10, while T-cells from
control mice secreted 65 pg/ml.
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Figure 6: IL-17 Secretion by T-Cells. Media collected from Control and SLE mice’ T-cell
cultures were used to measure IL-17 secretion at baseline conditions in pg/ml. Albumin levels
were measured in the urine pre experiment. Control mice had trace amounts of albumin, one SLE
mouse had albumin levels of 100, and the other SLE mouse had Albumin levels of 2000. T-cells
from control mice and SLE mice had average IL-17 secretion levels of 13.4 and 20.5 pg/ml
respectively. The SLE mouse with 100 Albumin had secretion levels of 13.7, while the SLE
mouse with high Albumin had secretion levels of 27.3 pg/ml.
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always produce more IL-17 than Control. Yet, when the autoimmune disease becomes
more severe, the SLE T-cells may be producing more of the inflammatory cytokine IL17.

IFN- y secretion is greaterfor SLE then Control T-cells.

Figure 7 compares the secretion of IFN- y between SLE and Control T-cells at
baseline conditions. The SLE mice had severe albumin (2000)levels, while the control
mice had minor (trace).The media from the cell cultures was run through an ELISPOT
assay, which forms spots based on the amount of IFN- y. The assay showed that the SLE
group created 156 spots while the Control group created 98 spots. This suggested that
SLE T-cells were producing more IFN- y then Control T-cells under baseline conditions.

SLE and Control T-cells in the presence ofANG-II increase IFN- y secretion equally.

SLE and Control T-cells were cultured in the presence of 10 uM of ANG-II to see
the effects on IFN- y secretion. Figure 8 indicates that ANG-II increase the production of
IFN- y by T-cells in both groups. In the Control group the number of spots produced in
the ELISPOT assay by IFN- y increased from 98 spots without ANG-II to 192 spots with
ANG-II(196% of control). Similarly in the SLE group, the number of spots jumped from
156 without ANG-II to 269 with ANG-II(172% of control). ANG-II did cause an
increase in IFN- y production, but did not cause any difference in the production of IFNy between the two groups.
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Figure 7: IFN- y Secretion by T-Cells. Media collected from Control and SLE mice
cultures were used to measure IFN- y secretion at baseline conditions by the formation of spots.
T-cells collected from SLE mice created more IFN- y based spots (156) than T-cells from control
mice (98).
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Figure 8: IFN- y Secretion by T-Cells in the Presence of ANG II. T-cell media collected from
Control and SLE mice were cultured in the presence or absence of ANG II. Media collected from
the four different cell cultures were used to measure IFN- y secretion by the formation of spots.
ANG II caused more IFN- y based spots to appear in the Control (+94), and SLE group (+114).
There was only a minor difference in the IFN- y based spots production between the two groups
in the presence of ANG II.
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Discussion
There is currently no cure for SLE,and patients with the disease must struggle
their entire lives to maintain health. It has been well documented that women with SLE
are at a much greater risk of dying from a cardiac related event then healthy women their
age (5). The main risk factor for developing cardiac problems in women with SLE is
hypertension, but the mechanism that leads to hypertension in SLE remains unknown.
Since the kidneys are the long-term regulators of blood pressure, it is commonly believed
that kidney damage is involved. SLE nephritis presents a plausible cause for the damage,
but not all patients with SLE develop nephritis. Instead it has been shown that renal
dysfunction, such as decreased GFR and water retention, has a higher correlation with
hypertension than nephritis (12).

Changes in the forces that oversee the activity of the nephrons, RVR and RBF,
preclude changes in renal function. Yet, these mechanics are tightly regulated in the
kidneys, and it takes direct damage to the renal tissue to alter their controls (8). In SLE
there is constant damage to tissues, as immune cells mistakenly identify and attack the
body. This autoimmunity directly causes inflammation, and it is well known that the
immune cells often lead to damage in the kidneys (1). Inflammation is a complex process
that requires inflammatory cytokines to communicate between cells, and the levels of
these cytokines dictate the severity of the inflammation caused tissue damage. This study
focused on the levels of the inflammatory c)^okines (IL-10, IL-17, IFN- y), and proposed
that the mechanism for SLE hypertension is centralized around the production of
cytokines by T-cells.
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To further test the role of inflammatory cytokines in the mechanism for SLE
hypertension, the first step was to analyze their rate of secretion by T-cells isolated from
Control and SLE mice. We predicted that there would be greater quantities of these
cytokines being secreted by SLE T-cells, which would mean greater recruitment and
activation of immune cells, potentially to the kidneys, and therefore more kidney damage.
The NZB WF1 mouse model was a great tool to study SLE hypertension, since it
mimicked the human disease, especially the increased MAP (Figure 4). The isolated Tcells from the mice were easy to culture, and after incubation provided great insight to the
circulating levels of the different inflammatory cytokines.

The results illustrated that SLE T-cells were secreting BL-10 at a greater level then
normal T-cells (Figure 5). Knowing that IL-10 is an anti-inflammatory cytokine makes
this result seem contradictory, but the role of IL-10 is more complex in an autoimmune
condition. While, it does act to reduce the number of T-cells in the circulation, it also
stimulates B-cells to produce antibodies (21). This is detrimental in an autoinunune
disease, because the increased numbers of antibodies continuously mistake the host tissue
as foreign threats. Ultimately, more and more immune cells are recruited to the site of the
antibodies, and the inflammation grows. In the kidneys of SLE patients, IL-10 may be
stimulating the inflammation, and therefore degrading the kidney function. Results from
this experiment showed that IL-10 production by SLE T-cells is almost 400% of Control
T-cells production. The high prevalence and autoimmune consequences of this cytokine
make it a potential player in the mechanism of SLE hypertension.

The pro-inflammatory cytokine IL-17 is known to recruit other inflammatory cells
and promote inflammation (19). It was hypothesized that SLE T-cells would secrete this
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cytokine at higher levels, but the results of the SLE group were variable. There was a
major disparity between the IL-17 production levels of the two SLE mice, which
correlated with major differences in their albumin levels. Albumin in the urine is a great
indicator of how much damage has occurred in the kidneys, since the protein is usually
too large to be filtered through the glomerulus (9). SLE is an unpredictable disease
because the symptoms do not all appear simultaneously. Usually in the NZBWFl mouse
model the disease begins to manifest around thirty-six weeks, and all the mice develop
severe symptoms soon after. The mice in this experiment were sacrificed exactly at
thirty-six weeks, and it seems that one of them had not yet fully developed SLE. That
mouse had only slight albumin in its urine, suggesting that it was beginning to develop
kidney damage, but at the moment was fairly similar to the Control mice (albumin trace).
The similar level of the pro-inflammatory IL-17 secretion by these two groups is
consistent with the lack of kidney damage, and suggests that this c)^okine contributes to
inflammation in the kidneys. The other SLE mouse with severe albumin had T-cells that
were producing IL-17 at almost 200% the rate of the Control. It is possible that the higher
levels of IL-17 were causing more inflammation in the kidneys, and therefore more
kidney damage in the SLE mouse with severe albumin. This suggests a possible role for
IL-17 secretion in the mechanism for SLE hypertension.

Similar to IL-17, EFN- y is also a cytokine known for promoting inflammation.
Therefore, we predicted that SLE T-cells would secrete more of the cytokine than Control
T-cells. The results indicated that at baseline conditions SLE T-cells were producing
IFN- y at about 150% that of Control production (Figure 7). The higher levels of the
inflammatory cytokine suggest more inflammation occurring in the kidneys of the SLE
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mice, and hence more renal dysfunction. Similar to the inflammatory c}^okines IL-10 and
IL-17, the results support the role of IFN- y in promoting SLE hypertension through
inflammation in the kidneys.

SLE T-cells secreted all three of the cytokines studied in this experiment at higher
levels than Control T-cells, and all three fit in the proposed mechanism for SLE
hypertension. Yet, it remained unclear what stimulated the T-cells to increase production.
beyond the effects of IL-2(which is normally present in vitro). The potential stimulus
studied in this experiment was ANG II, since the hormone is well known to increase
blood pressure (8). Previous experiments have shown that in some mouse models of
hypertension, ANG II only promotes hypertension and renal dysfunction if immune cells
are present (26). There is no concise evidence that ANG II levels are higher in patients
with SLE. This lead to the hypothesis that ANG II was promoting hypertension by
increasing inflammatory cytokine production, and therefore inflammation in the kidneys.
Due to a lack of time and resources only the effects of ANG II on the cytokine IFN- y
were studied. Results showed that ANG II increased IFN- y production about a 100% m
both the SLE and Control group of T-cells (Eigure 8). It had was hypothesized that SLE
T-cells would see a sharper increase in BFN- y production then control T-cells in the
presence of ANG II. This would have supported the role of ANG II as the stimulus for
SLE T-cells activation, but ANG II caused an equal increase in production in the gioups.
The results indicate that ANG II may be promoting inflammation in the kidneys as a
means to promote hypertension. Yet, in the case of SLE there was no reason to suspect
that ANG II is the trigger that causes the high levels of inflammatory cytokine
production.
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Ultimately the study supported the role of inflammatory cytokines in the
development of renal damage. The results showed that three c}nokines are being
produced at greater levels by SUE T-cells. Knowing the chronic inflammation in SEE, the
high prevalence of hypertension in SEE patients, and the previous studies that support the
role of inflammation in hypertension, it is important to further study inflammatory
cytokines in the development of SEE hypertension. It needs to be discovered what causes
T-cells in SEE to activate and promote inflammation. ANG II did increase the
pioduction of cytokines, but this increase was not specific to just SEE. Since SEE
patients are at such a higher risk for developing hypertension, there might be a stimulus
that specifically promotes SEE T-cells to activate. Since SEE is such a gender specific
disoider, a potential candidate may be estrogen.

For most people the risk of a cardiac event can be prevented with simple things
like exercise and diet. Yet, for women with SEE the risk of a cardiac event is present
regardless of personal choices on fitness, and greatly increases

their risk for mortality,

The modern medication for these patients is focused on only mellowing the symptoms of
hypertension, since the cause IS not yet understood. More research on the inflammatory
mechanisms that promote hypertension, would improve the prognosis for not only SEE
patients, but patients of several autoimmune diseases and hypertension in general.
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